Search results
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
Benzinga via Yahoo Finance· 2 years agoThe FDA approved Bayer AG's (OTC: BAYRY) supplemental marketing application for Nubeqa...
Bayer says 2024 sales of prostate cancer drug above $1 billion
Reuters via Yahoo News· 1 month agoBayer on Thursday predicted at least $1 billion in 2024 sales for prostate cancer drug Nubeqa, which...
Bayer wins U.S. priority review of drug against metastatic prostate cancer
Reuters via Yahoo News· 2 years agoBayer's Nubeqa drug won priority review status from the U.S. Food and Drug Administration, as the...
Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?
Zacks via Yahoo Finance· 4 months agoBayer AG BAYRY put up a dismal performance in 2023, even though other players in the large-cap...
UPDATE 1-Drugmaker Orion sees inflation hit in H2 after quarterly profit beat
Reuters via Yahoo Finance· 2 years agoFinnish drugmaker Orion on Friday reported better-than-expected quarterly earnings helped by strong sales of prostate cancer treatment Nubeqa, but warned cost inflation would hit its profits ...
Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues
Zacks via Yahoo Finance· 2 months agoBayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased...
Bayer (BAYRY) Banks on Pipeline Progress Amid Challenges
Zacks via Yahoo Finance· 1 month agoBayer AG BAYRY presented the latest developments on the road to transform its pharma business to...
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
Zacks via Yahoo Finance· 2 years agoBayer AG BAYRY reported first-quarter 2022 core earnings of 99 cents per American Depositary Receipt...
Bayer (BAYRY) Partners Twist Bioscience for Drug Discovery
Zacks via Yahoo Finance· 7 months agoBayer AG BAYRY entered into an antibody discovery, option and license agreement with Twist...
3 Growth Stocks Poised for Huge Gains in 2023
Motley Fool· 1 year agoPharmaceutical companies Bayer (OTC: BAYR.Y), Eli Lilly (NYSE: LLY), and AstraZeneca (NASDAQ: AZN) had big years last year, bucking the rest of the...